Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216835 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase 1 study of Relapsed or Refractory Classical Hodgkin Lymphoma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 14
- Study locations
NCT05216835: Completed Phase 1 study of Relapsed or Refractory Classical Hodgkin Lymphoma, sponsored by AstraZeneca.
NCT05216835 is a Phase 1 study of Relapsed or Refractory Classical Hodgkin Lymphoma that has completed, run by AstraZeneca. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05216835, a Phase 1 study of Relapsed or Refractory Classical Hodgkin Lymphoma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 14
- Study locations
Study Summary
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
Primary Outcome
The safety and tolerability of sabestomig in participants with r/r cHL were assessed.
Conditions Studied
Interventions
- DRUG Sabestomig (AZD7789)
Study Locations (14)
Other
- Research Site - København Ø
- Research Site - Lille
- Research Site - Bologna
- Research Site - Naples
- Research Site - Valencia
- Research Site - Manchester
- Research Site - Oxford
California
- Research Site - Duarte
Florida
- Research Site - Miami
Minnesota
- Research Site - Rochester
New York
- Research Site - New York
Texas
- Research Site - Houston
Ontario
- Research Site - Toronto
Quebec
- Research Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-03-18 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 1 |
What the finished NCT05216835 record still lists
NCT05216835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Relapsed or Refractory Classical Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Sabestomig (AZD7789) is the first listed.
NCT05216835 lists 14 locations in 8 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT05216835 about?
NCT05216835 is a clinical study titled "Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma". The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
What is the current status of trial NCT05216835?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2022-03-18. Estimated completion is 2025-09-04.
What conditions does trial NCT05216835 study?
This clinical trial studies the following conditions: Relapsed or Refractory Classical Hodgkin Lymphoma.
What interventions are being tested in trial NCT05216835?
The interventions under investigation include: Sabestomig (AZD7789) (DRUG).
Who is sponsoring clinical trial NCT05216835?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05216835 being conducted?
This trial has 14 study locations across California, Florida, Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05216835's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI